Cervarix Vaccine Programme to Cost UK Government £5.5 Billion

Over 73 Years Before Targeted Annual Number of Women’s Lives are Saved.
By: Leslie Carol Botha, Vice President, SaneVax, Inc.
May 18, 2011 - PRLog -- Let’s bypass the usual conversation on arbitrating a price on the value of a person’s life.  The Cervarix programme in the United Kingdom may become bankrupt before even saving one woman’s life from cervical cancer.

Freda Birrell, Secretary of SANE Vax Inc. has been communicating with government officials in the United Kingdom for the past two years about the global concerns regarding the safety and efficacy of the HPV vaccines.  Unfortunately, it appears the UK government just like the U.S. CDC and FDA – do not perceive the value of their constituent’s lives; nor do they appear to be concerned over the death and injuries of previously healthy adolescent girls in their respective countries.  Children are our future!   When the government of any country turns their back on them, it is cause for great public concern.

Birrell determined if the life of a child is not valued by the government then it was time to analyze present information they can relate to – in this case a financial investment in a vaccine programme that will cost the UK government billions before a return is seen on their investment. Sad but true.

Birrell and her analytical team have compiled data and graphs from Cancer UK Research on cervical cancer mortality rates in a document titled: HPV 2 Cervarix Economic Costs in the United Kingdom.

The analytical team developed an economic formula to determine the cost of the Cervarix programme to the UK government by using Cancer UK Research data and making basic assumptions on cost of vaccination for targeted demographic per annum. By doing so, they determined how long it will take before perceived benefits/results of the vaccination programme will be apparent. The data translates into a hefty financial subsidy benefiting GlaxoSmithKline, but an alarmingly low rate of return for the UK government and its citizens.

HPV 2 Cervarix Economic Costs in the United Kingdom [visit http://sanevax.org/news-blog/wp-content/uploads/2011/05/S... for more information.]

According to Cancer Research UK – female mortality rates from cervical cancer rise slightly between ages 20 to 24 – but do not peak until age 45 to 49 – with the greatest increase in women over the age of 80.  (Table 1 & 2)

Cancer Research UK reports mortality rates from cervical cancer decreased from 8.3 deaths per 100,000 in 1971 to 2.4 deaths in 2008. (Table 3)

Analysis assumptions based on available data from Cancer Research UK and the UK government on the vaccination programme follows:

•   Total deaths (Cancer Research UK) to age 84 at 837 per year.
•   75% of deaths saved with the vaccination program i.e. 628 per year. *
•   Cost per person vaccinated - £200.00 assumed.  
•   Average no. of vaccinations administered per year (12 year olds) at 378,289.
•   The Cancer Research UK deaths/5 year groups have been divided by 5 for an average annual     figure of deaths due to cervical cancer.
•   JCVI assumes HPV2 Cervarix vaccination efficacy will last 10 years. **
•   It will take 73 years to vaccinate a total cycle of the female population (12 year olds to 84 year olds)
* Cervarix vaccine was introduced to protect against HPV 16 & 18, the two viruses associated with 70% of cervical cancer cases. There have been indications that this vaccine may provide additional benefits due to cross-reactivity.

** Booster shots not included in calculations

In a dramatic table, Birrell has compiled an Analysis of the Annual HPV Vaccination Programme that shows that the first deaths saved from cervical cancer – (based on administration of Cervarix to 12 year old adolescent girls in 2008) will not be seen until the year 2016 (1.2 deaths per 100,000) at a cost to the government of £75,657,800 annually with a total cost of £681 million.  

In other words…over 75 million £ will have been spent each year on the vaccine programme for 9 years to save one life….which Cancer Research UK has shown to be the mortality rate for this age group. (Table 2)  

Now are you listening?

But wait there is more…according to Birrell’s research –

•   It will take 28 years to save the first 628 lives, the annual target at a cost of £3.2 million for each life saved.

•   It will take 73 years to save 628 lives annually - At a cost of £340,360 for each life saved.

The analysis also projects a total of 16,227 lives in the UK will be saved in total over the first 73 years – with an average of only 222 lives saved annually. In addition, it will take 240 years before the cost of a life saved falls below £150,000.

Add in the fact that the vaccine efficacy is only expected to last 10 years, meaning the girls first administered the vaccination series in their teens will need a booster in their 20’s…and so on up the ladder.  Those pro-inflated costs and the costs associated with recommended annual pap screening were not included in Birrell’s analysis. Costs associated with vaccine adverse injuries were also not used in this equation.

Birrell was unable to uncover information in the public domain on the financial benefits to the UK government from this vaccination programme - justifiably raising serious questions over the Pharma/government agenda behind the HPV Vaccine programme.  

Bottom line – bottom dollar – the UK government will spend £5.5 billion over the first 73 years of the vaccination programme with the expectation of saving 628 lives each year but with the current efficacy being only expected to last 10 years then these costs are grossly underestimated if a booster jab is introduced.  If no booster jab is introduced and the efficacy falls at around age 22, it would  render the previous ten years a total waste of public funds, accomplishing nothing more than giving false hope to all the participants who believed they would be ‘armed for life’ against cervical cancer.  

SANE Vax Inc. can see no economic justification for this programme. We believe the UK government has been misled by the pharmaceutical industry regarding the risk to benefit profile of HPV vaccine programmes.  Should other government leaders start doing the math regarding the cost of each life saved, we believe they would unveil HPV vaccination programmes as a colossal waste of public health funds with very few benefits to their constituents.

# # #

SaneVax believes only Safe, Affordable, Necessary & Effective vaccines and vaccination practices should be offered to the public. Our primary goal is to provide scientific information/resources for those concerned about vaccine safety, efficacy and need.
Source:Leslie Carol Botha, Vice President, SaneVax, Inc.
Email:***@gmail.com Email Verified
Tags:Cervarix, HPV 2 vaccine, UK, Public Health Funds, Government, Pharmaceutical Industry
Industry:Consumer, Health
Location:Fort Collins - Colorado - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SaneVax, Inc. PRs
Trending News
Most Viewed
Top Daily News

Like PRLog?
Click to Share